加拿大皇家银行(RBC)发布最新研报,将福泰制药(Vertex Pharmaceuticals)的股票评级从"板块同步"调升至"跑赢大盘"。
与此同时,该行将福泰制药的目标股价从455美元大幅上调至546美元,显示出对该公司未来业绩的强劲信心。
此次评级调整反映了分析师对福泰制药在创新药物研发和市场拓展方面的积极预期。
加拿大皇家银行(RBC)发布最新研报,将福泰制药(Vertex Pharmaceuticals)的股票评级从"板块同步"调升至"跑赢大盘"。
与此同时,该行将福泰制药的目标股价从455美元大幅上调至546美元,显示出对该公司未来业绩的强劲信心。
此次评级调整反映了分析师对福泰制药在创新药物研发和市场拓展方面的积极预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.